A parallel-group prevention, Phase II, partially blinded, multi-stage study to investigate the immunogenicity and safety of Pentavalent Meningococcal ABCYW Vaccine formulations compared with licensed meningococcal vaccines when administered alone in healthy children (2 to 9 years of age) or concomitantly with routine pediatric vaccines in toddlers (12 to 15 months of age) and infants (2 months of age).
Active, not recruitingCTIS2023-510465-10-00
Sanofi Pasteur Inc.Meningococcal immunization
Start: 2025-03-10Target: 250Updated: 2025-11-13